https://encoded.com/encoded-therapeutics-presents-new-clinical-data-from-polaris-phase-1-2-trials-of-etx101-gene-therapy-in-dravet-syndrome-at-the-asgct-2026-presidential-symposium/2026-07-23T17:57:50-04:00https://encoded.com/encoded-therapeutics-presents-new-preclinical-data-at-asgct-2026-highlighting-precision-vector-engineering-across-neurology-programs/2026-07-23T17:59:01-04:00https://encoded.com/encoded-therapeutics-doses-first-patient-in-pivotal-study-of-etx101-for-dravet-syndrome-and-reports-broader-portfolio-progress/2026-07-23T18:00:29-04:00https://encoded.com/encoded-therapeutics-to-present-etx101-data-in-dravet-syndrome-at-the-2026-asgct-presidential-symposium/2026-07-23T18:02:14-04:00https://encoded.com/encoded-therapeutics-announces-fda-alignment-initiation-of-pivotal-study-and-asgct-presidential-symposium-presentation-of-etx101-in-dravet-syndrome/2026-07-23T18:03:05-04:00https://encoded.com/encoded-therapeutics-announces-u-s-fda-breakthrough-therapy-designation-granted-to-etx101-for-the-treatment-of-dravet-syndrome/2026-07-23T16:35:57-04:00https://encoded.com/encoded-therapeutics-highlights-progress-in-dravet-syndrome-program-and-pipeline-ahead-of-company-presentation-at-44th-annual-j-p-morgan-healthcare-conference/2026-07-23T16:35:58-04:00https://encoded.com/encoded-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference-on-january-12-2026/2026-07-23T16:36:00-04:00https://encoded.com/encoded-therapeutics-strengthens-clinical-leadership-team-with-appointment-of-professor-joseph-sullivan-m-d-as-vice-president-of-clinical-development/2026-07-23T16:36:01-04:00https://encoded.com/encoded-therapeutics-presents-positive-interim-efficacy-data-from-initial-dose-levels-of-phase-1-2-trials-evaluating-etx101-gene-therapy-in-dravet-syndrome/2026-07-23T16:36:03-04:00https://encoded.com/encoded-therapeutics-to-present-interim-phase-1-2-clinical-data-on-etx101-the-first-one-time-gene-therapy-in-development-for-dravet-syndrome-at-the-2025-american-epilepsy-society-annual-meeting/2026-07-23T16:36:15-04:00https://encoded.com/new-preclinical-data-from-encoded-therapeutics-demonstrate-therapeutic-potential-of-its-one-time-non-opioid-gene-therapy-candidate-for-chronic-pain/2026-07-23T16:36:17-04:00https://encoded.com/encoded-therapeutics-announces-regenerative-medicine-advanced-therapy-rmat-designation-granted-by-u-s-fda-for-etx101-in-scn1a-dravet-syndrome/2026-07-23T16:36:21-04:00https://encoded.com/encoded-therapeutics-presents-promising-new-data-for-cns-gene-therapy-programs-at-the-asgct-28th-annual-meeting/2026-07-23T16:36:23-04:00https://encoded.com/encoded-therapeutics-to-present-new-data-for-cns-gene-therapy-programs-at-the-asgct-28th-annual-meeting/2026-07-23T16:36:25-04:00https://encoded.com/encoded-therapeutics-reports-clinical-progress-of-etx101-gene-therapy-for-dravet-syndrome-recaps-2024-corporate-achievements-and-provides-2025-outlook/2026-07-23T16:36:27-04:00https://encoded.com/encoded-demonstrates-therapeutic-potential-of-a-vectorized-mirna-based-approach-for-angelman-syndrome-at-the-fast-annual-global-science-summit/2026-07-23T16:36:29-04:00https://encoded.com/encoded-therapeutics-presents-preclinical-data-across-its-gene-therapy-portfolio-at-the-27th-annual-meeting-of-the-american-society-of-gene-cell-therapy-asgct/2026-07-23T16:36:30-04:00https://encoded.com/encoded-therapeutics-provides-pipeline-updates-from-its-vector-engineering-platform-ahead-of-four-preclinical-presentations-at-the-27th-annual-meeting-of-the-american-society-of-gene-cell-therap/2026-07-23T16:36:32-04:00https://encoded.com/encoded-therapeutics-announces-uk-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/2026-07-23T16:36:34-04:00https://encoded.com/encoded-therapeutics-announces-135-million-series-d-financing-to-support-first-clinical-trials-in-scn1a-dravet-syndrome-and-advance-preclinical-pipeline-of-gene-therapies-for-debilitating-neurologic/2026-07-23T16:36:45-04:00https://encoded.com/encoded-therapeutics-expands-gene-therapy-leadership-with-key-appointment-and-promotion/2026-07-23T16:36:47-04:00https://encoded.com/encoded-therapeutics-strengthens-senior-leadership-team-with-key-appointments-in-regulatory-and-human-resources-functions/2026-07-23T16:36:48-04:00https://encoded.com/encoded-therapeutics-expands-leadership-team-with-key-appointments-adding-expertise-in-manufacturing-and-corporate-development/2026-07-23T16:36:50-04:00https://encoded.com/encoded-therapeutics-inc-announces-104-million-series-c-financing-to-advance-lead-gene-therapy-program-in-dravet-syndrome-and-unveils-its-precision-gene-therapy-platform/2026-07-23T16:36:51-04:00https://encoded.com/encoded-therapeutics-announces-us-ind-clearance-and-australian-cta-approval-for-dravet-syndrome-gene-therapy-candidate-etx101/2026-07-23T16:36:53-04:00https://encoded.com/encoded-therapeutics-addresses-common-source-of-gene-therapy-toxicity-while-achieving-precise-brain-expression-in-non-human-primates-presented-at-the-american-society-of-gene-and-cell-therapy-26th-an/2026-07-23T16:36:55-04:00https://encoded.com/encoded-therapeutics-presents-nonclinical-data-showing-genomic-medicine-platform-yields-selective-expression-to-optimize-gene-therapy-performance-at-the-american-society-for-cell-and-gene-therapy-25th/2026-07-23T16:36:56-04:00https://encoded.com/encoded-therapeutics-presents-data-showing-that-children-with-dravet-syndrome-experience-early-substantial-neurodevelopment-deficits-and-seizure-burden-at-the-american-epilepsy-society-2021-annual-m/2026-07-23T16:36:57-04:00https://encoded.com/encoded-therapeutics-to-present-initial-envision-natural-history-study-data-of-children-with-scn1a-dravet-syndrome-at-the-american-epilepsy-society-2021-annual-meeting/2026-07-23T16:36:59-04:00